Small molecule inhibitors of ebola and lassa fever viruses

1. A compound represented by formula I:

or a pharmaceutically acceptable salt, solvate, hydrate, enantiomer or stereoisomer thereof; wherein, independently for each occurrence,

W is

R is

X is

n is 1 or 2;

A is adamant-1-yl, 3-alkyladamant-1-yl, 5-alkyladamant-1-yl or 3,5-dialkyladamantyl;

R 2 is hydrogen, halo, alkyl or haloalkyl;

R 3 is hydrogen, halo, alkyl, haloalkyl, alkenyl, or aryl;

R 4 is hydrogen or alkyl;

R 5 is hydrogen, alkyl, haloalkyl or alkyl substituted with one or two substituents independently selected from halo, cyano, haloalkyl, aralkyl, hydroxy, alkyloxy, carboxy, alkyloxycarbonyl, haloalkyloxycarbonyl, carbocyclyloxycarbonyl, aryloxycarbonyl, carbocyclylalkyloxycarbonyl, and aralkyloxycarbonyl; and

R 6 is phenyl or pyridinyl, optionally substituted with one, two, three or four substituents selected from hydroxy, alkyloxy, tert-butyldimethylsilyloxy, methylenedioxy, ethylenedioxy, propylenedioxy, butylenedioxy, alkyl, haloalkyl, trifluoromethyl, fluoro, chloro, bromo, iodo, cyano, nitro, acetylamino, carboxy and alkyloxycarbonyl;

provided the compound is not

2. A compound, or pharmaceutically acceptable salt, solvate, hydrate, enantiomer or stereoisomer thereof, selected from

3. The compound of claim 1 , wherein R 1 is

4. The compound of claim 1 , wherein R 1 is phenyl, naphth-1-yl, naphth-2-yl, pyridin-2-yl or pyridin-3-yl.

5. The compound of claim 1 , wherein R 2 is hydrogen.

6. The compound of claim 1 , wherein R 3 is hydrogen.

7. The compound of claim 1 , wherein R is

and X is

8. The compound of claim 1 , wherein A is adamant-1-yl or 3,5-dialkyladamantyl.

9. The compound of claim 1 , wherein R 5 is hydrogen.

10. The compound of claim 2 , wherein the compound is

11. The compound of claim 1 , wherein R is

12. The compound of claim 1 , wherein R 6 is